Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks
John K. French, MB, PhDa,
Thomas A. Hyde, MBa,
Hitesh Patel, MBa,
David J. Amos, MBa,
Stephanie C. McLaughlin, PhDa,
Bruce J. Webber, DSR (Diagnostic)a and
Harvey D. White, MB, DSca
a Cardiovascular Research Unit, Cardiology Department, Green Lane Hospital, Auckland, New Zealand
View larger version (13K):
[in a new window]
|
Figure 1 Late actuarial survival after randomization to receive streptokinase or placebo after myocardial infarction. The log-rank comparison between the streptokinase and placebo groups was p = 0.022. At 5 years survival was 84% (95% confidence interval [CI] 76 to 90) in the streptokinase group and 70% (95% CI 60 to 77) in the placebo group (p = 0.023). At 12 years, survival was 66% (95% CI 55 to 75) in the streptokinase group and 51% (95% CI 41 to 60) in the placebo group (p = 0.022).
|
|
View larger version (18K):
[in a new window]
|
Figure 2 Late survival after myocardial infarction according to the Thrombolysis in Myocardial Infarction (TIMI) flow grade at 3 to 4 weeks. (A) The log-rank three-way comparisons between TIMI 3, 2 and 0–1 flow, truncated at 1, 5 and 12 years, were p = 0.005, 0.005 and 0.028, respectively. The log-rank two-way comparisons of TIMI 3 versus TIMI 2 flow at 1, 5, and 12 years were p = 0.047, 0.045 and 0.36, respectively. The log-rank two-way comparisons of TIMI 3 versus TIMI 0–1 flow, truncated at 1, 5 and 12 years, were p = 0.001, 0.0009 and 0.006, respectively. The log-rank two-way comparisons of TIMI 0–1 versus TIMI 2 flow, truncated at 1, 5 and 12 years, were p = 0.22, 0.25 and 0.15, respectively. (B) Survival adjusted for the ejection fraction and exercise duration; the log-rank comparisons, truncated at 5 and 12 years, were p = 0.026 and 0.27, respectively.
|
|
|
